Beverly Hills Cancer Center | Beverly Hills, CA

Research site
8900 Wilshire Boulevard Suite 200, Beverly Hills, California, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


28 of 55
Status: Active
Trial type: Interventional
Funder type: Industry

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (MagnetisMM-20)

The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elran...

Multiple Myeloma
Drug: Maplirpacept
Drug: Elranatamab

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Dexamethasone Mouth Rinse
Drug: LHRH Agonist

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with place...

Active, not recruiting
Breast Cancer
Drug: Placebo
Drug: Palbociclib

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after...

Active, not recruiting
Breast Neoplasms
Drug: Placebo
Drug: Abemaciclib

This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizu...

Active, not recruiting
Endometrial Cancer
Solid Tumor, Unspecified, Adult
Drug: Fruquintinib
Drug: Tislelizumab

The purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular ly...

Active, not recruiting
Drug: Parsaclisib

The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in part...

Active, not recruiting
Endometrial Cancer
Breast Cancer
Drug: Trastuzumab
Drug: Everolimus

This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).

Active, not recruiting
Colorectal Cancer
Pancreatic Cancer
Drug: NBF-006

This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or meta...

Active, not recruiting
Nonsmall Cell Lung Cancer
Drug: HS-10296

This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with othe...

Active, not recruiting
Non-squamous, Non-Small-Cell Lung Cancer
Drug: ezabenlimab
Drug: BI 836880

To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and...

Chemotherapy-induced Peripheral Neuropathy
Drug: Placebo
Drug: thrombomodulin alfa

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, c...

Active, not recruiting
Nonsmall Cell Lung Cancer
Drug: Immune checkpoint inhibitors or docetaxel
Device: NovoTTF-200T

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting
Breast Cancer
Drug: Abemaciclib
Drug: Standard Adjuvant Endocrine Therapy
Locations recently updated

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the t...

Multiple Myeloma
Drug: Bortezomib
Drug: Elotuzumab

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/ref...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab (PF-06863135)
Recently updated

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer ther...

Multiple Myeloma
Drug: Elranatamab + lenalidomide + dexamethasone
Drug: Elranatamab + Nirogacestat

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), opt...

Advanced Non-Small Cell Squamous Lung Cancer
Epidermal Growth Factor Receptor C797S
Drug: BDTX-1535 monotherapy

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Metastatic Cancer
Advanced Cancer
Drug: MRTX849
Drug: Afatinib

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanc...

Active, not recruiting
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Drug: Sitravatinib
Drug: Docetaxel

This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants w...

Metastatic Breast Cancer
Drug: Letrozole
Drug: Goserelin

Trial conditions

Non-Small-Cell Lung Carc... (17 trials)
Breast Cancer (16 trials)
Lung Cancer (15 trials)
Colorectal Cancer (4 trials)
Multiple Myeloma (4 trials)
Plasma Cell Cancer (4 trials)
Carcinoma (3 trials)
Cachexia (2 trials)
Endometrial Cancer (2 trials)
Melanoma (2 trials)

And 24 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems